皮克罗化物II通过向VP1聚合酶来破坏IBDV复制
Donghu Zhang1, Jing Wang2, Huansheng Wu3
1School of Pharmacy, China Medical University, Shenyang, Liaoning 110122, PR China; Department of Pharmacy, the First Hospital of China Medical University, Shenyang, Liaoning 110001, P R China.
Veterinary microbiology
|July 20, 2024
概括
皮克罗斯II通过向病毒聚合酶,有效地抑制传染性病病毒 (IBDV) 复制. 这种天然化合物表现出持久的抗病毒作用,为家禽IBDV感染提供了有前途的治疗选择.
科学领域:
- 病毒学 病毒学
- 禽类的健康 禽类的健康
- 自然产品化学 自然产品化学
背景情况:
- 传染性病病毒 (IBDV) 在家禽中造成重大经济损失,原因是高死亡率和避开疫苗的菌株.
- 由于当前疫苗的局限性,家禽业迫切需要针对IBDV的新型抗病毒疗法.
- 目前对IBDV的治疗方法有限,这凸显出需要新的治疗策略.
研究的目的:
- 为了评估皮克二的抗病毒功效,一种天然的化物糖化物,对IBDV.
- 阐明皮克罗二号在抑制IBDV复制的作用机制.
- 评估皮克二的治疗潜力,作为IBDV的抗病毒药物.
主要方法:
- 在体外抗病毒测试中,使用感染IBDV的DF-1细胞.
- 时间加值和抗病毒持续时间分析以确定病毒复制的目标阶段.
- 生物化学试验用于研究皮克二的与IBDV VP1聚合酶和VP3.3的相互作用.
- 针对VP1的局部导向突变发生,以确定关键结合部位.
主要成果:
- 皮克罗西德II在DF-1细胞中显著抑制了IBDV复制的剂量依赖性.
- 皮克二的抗病毒作用持续超过72小时,表明持续的治疗作用.
- 发现皮克罗化物II可以抑制IBDV生命周期的细胞复制阶段.
- 该化合物通过与其活性口袋结合,损害IBDV VP1聚合酶活性,破坏VP1-VP3相互作用.
- 在关键的VP1结合部位的突变取消了聚合酶功能和病毒复制.
结论:
- 皮克罗化物II通过抑制病毒聚合酶活性,对IBDV表现出强烈的抗病毒活性.
- 这种天然化合物破坏了重要的病毒复制步骤,包括聚合酶功能和蛋白质相互作用.
- 皮克罗化物II代表了一种有希望的化合物,用于开发针对家禽IBDV的新型抗病毒疗法.
相关概念视频
piRNA - Piwi-interacting RNAs
6.8K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
6.8K
Leaky Scanning
5.1K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.1K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
Retroviruses
12.2K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
12.2K
Eukaryotic Transcription Inhibitors
9.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


